PRA Health Sciences Inc (PRAH) Receives Consensus Rating of “Buy” from Brokerages
Shares of PRA Health Sciences Inc (NASDAQ:PRAH) have been assigned a consensus recommendation of “Buy” from the twelve research firms that are presently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $113.50.
PRAH has been the subject of several recent analyst reports. Evercore ISI initiated coverage on shares of PRA Health Sciences in a research note on Thursday, October 4th. They set an “inline” rating and a $120.00 price objective for the company. UBS Group initiated coverage on shares of PRA Health Sciences in a research note on Tuesday, October 9th. They set a “neutral” rating for the company. BidaskClub lowered shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 11th. SunTrust Banks boosted their target price on shares of PRA Health Sciences to $120.00 and gave the company a “buy” rating in a research note on Monday, November 5th. Finally, Zacks Investment Research lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd.
NASDAQ PRAH traded up $0.12 on Friday, hitting $97.12. 308,696 shares of the stock were exchanged, compared to its average volume of 559,338. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $6.25 billion, a price-to-earnings ratio of 30.35, a PEG ratio of 1.20 and a beta of 1.10. PRA Health Sciences has a 52-week low of $79.20 and a 52-week high of $121.98.
Institutional investors and hedge funds have recently modified their holdings of the company. Price Capital Management Inc. purchased a new stake in shares of PRA Health Sciences during the third quarter valued at $121,000. Mount Yale Investment Advisors LLC raised its holdings in shares of PRA Health Sciences by 103.6% in the second quarter. Mount Yale Investment Advisors LLC now owns 1,704 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 867 shares in the last quarter. Parallel Advisors LLC raised its holdings in shares of PRA Health Sciences by 930.9% in the third quarter. Parallel Advisors LLC now owns 1,804 shares of the medical research company’s stock valued at $199,000 after acquiring an additional 1,629 shares in the last quarter. Bremer Trust National Association bought a new stake in shares of PRA Health Sciences in the third quarter valued at about $205,000. Finally, Gideon Capital Advisors Inc. bought a new stake in shares of PRA Health Sciences in the third quarter valued at about $207,000. 97.23% of the stock is owned by hedge funds and other institutional investors.
About PRA Health Sciences
PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.
Featured Story: Trading signals using Bollinger bands
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.